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Regarding “Problems with the dissemination of up-
to-date information on the results of endograft
repair for abdominal aortic aneurysm”
To the Editors:
Dr Rutherford, in a recent editorial (J Vasc Surg
1999;29:1167-9), highlighted the need for the prompt dis-
semination of information about structural defects detected
in endovascular devices used for abdominal aortic aneurysm
repair. He cited suture breaks in Stentor (Mintec, Bermuda)
and Vanguard (Boston Scientific Corporation, Nantick,
Mass) devices as an example of a potentially important dis-
covery disclosed to the vascular surgical community with
less than optimum efficiency, and he criticized the “late”
actions of both the Boston Scientific Corporation and the
EUROSTAR Registry.
Although the undersigned committee members of the
EUROSTAR have no responsibility for the actions of the
Boston Scientific Corporation, we would like to point out
that all European customers were informed by the compa-
ny about a report of suture breaks in their devices by letter
as early as November 1997. This was well before any
rumors began to circulate about structural defects in these
devices at scientific meetings. The letter described observa-
tions made by Riepe, Unscheid, Stelter, et al. Before receipt
of this letter, the EUROSTAR Organization was unaware of
the problem, the reason being that plain abdominal x-ray,
which is the most effective method for the detection of
suture break, was not included in the study protocol (it was
incorporated immediately after receipt of the notice from
the Boston Scientific Corporation).
In response to the information disclosed by the Boston
Scientific Corporation, EUROSTAR initiated an indepen-
dent study (outside of the standard registry protocol) of
suture breaks in Stentor and Vanguard devices. Plain
abdominal x-ray films from patients in 15 EUROSTAR cen-
ters were examined in a central “core-lab” to determine the
prevalence of suture break. To avoid unnecessary concern to
the patients, it was decided not to call the patients specially
but to arrange the additional x-ray examination at their next
scheduled follow-up visit. EUROSTAR delayed issuing any
statement pending the completion of this study. The results
in 98 patients to which Dr Rutherford referred were sent to
the Safety Committee of the Dutch Society for Vascular
Surgery and to the Boston Scientific Company in April
1998. At the same time, a summary, together with advice
for clinicians on the basis of the results, was circulated wide-
ly to vascular clinicians in Europe and the United States. An
abstract was submitted and accepted for presentation at the
October 1998 meeting of the European Society for Vascular
Surgery, and, subsequently, the data have been reported at
numerous meetings around the world.
In retrospect, the fact that we did not identify the
devices and the manufacturer in our abstracts does appear
to be an important omission. However, we considered
that the company itself had the primary responsibility to
disclose this information to the professional world. We did
explicitly identify Stentor and Vanguard as the devices
involved in our presentations.
Although we do not accept that there were serious
deficiencies in the standards of reporting of the suture
break phenomenon by EUROSTAR, we agree with Dr
Rutherford that the incident has raised some very impor-
tant issues relating to patient safety and the responsibilities
of clinical research workers. There is, indeed, a risk that
researchers may find themselves held liable for witholding
essential information from the professional and public
domain if they do not respond promptly to disclose evi-
dence of device failure. But there is also a risk, not men-
tioned in the editorial, that premature allegations of device
failure could expose researchers to claims, from manufac-
turers, for compensation for commercial damage. The
effect on the patients themselves of being subjected to
unnecessary alarm should not be forgotten either. These
risks are particularly high when harmful clinical effects
because of the alleged device failure are not obvious. In
view of the legal implications, it may well be appropriate for
clinicians to take professional advice before entering into
research contracts with industrial companies and even to
insure themselves against the risk of litigation in relation to
their work.
With the acknowledgment that public safety is of para-
mount importance, the least that can be expected of organi-
zations such as EUROSTAR is that they will verify the facts
to their own satisfaction before raising alarm about faults or
defects detected in medical devices. As far as the issue in
question is concerned, we believe that the actions taken by
EUROSTAR and the Boston Scientific Corporation were
both timely and effective in alerting the vascular community
to the occurrence of suture breaks in Stentor and Vanguard
devices. To date, there is no unequivocal evidence of associ-
ation between suture breaks and clinical complications.
Studies are ongoing within EUROSTAR, and it is consid-
ered that preparation of a full manuscript for publication
should await the acquisition of more conclusive data on this
vital point.
As more devices become available to clinicians, there is a
growing demand for information about the relevant efficacy
of each in comparison with its competitors. We believe that
some caution is justified with regard to direct head-to-head
comparison between the performance of different devices
because many factors are likely to be involved. However,
EUROSTAR is under considerable pressure to make this
type of information available, and we recognize the need to
respond. In a recent presentation at the meeting for the
Society for Vascular Surgery/International Society for
Cardiovascular Surgery, North American Chapter (manu-
script submitted to the Journal of Vascular Surgery), we
compared the early complication rates associated with the
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different types of endograft used by EUROSTAR collabora-
tors. Two devices were identified with significantly higher
primary procedural failure rates than the others.
It was precisely because of the concerns raised by Dr
Rutherford that the EUROSTAR Registry was estab-
lished. Our experience to date has reassured us that there
is no conflict of interest between device manufacturers and
clinicians, or indeed the patients, all of whom want to see
the potential benefits of the endovascular approach for
abdominal aortic aneurysm repair fully realized.
We are grateful to Dr Rutherford whose comments have
been of particular value to the EUROSTAR Organization.
Peter L. Harris, MD, FRCS
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